Purpose: To perform an analysis of the results obtained with radiotherapy in patients with either resectable or unresectable cholangiocarcinoma of the proximal bile ducts. Emphasis will be paid to analyse the role of radiotherapy, particularly brachytherapy
Introduction
Surgical resection continues to be the only treatment offering a chance of long-term survival to patients with cholangiocarcinoma of the hepatic hilus and common bile duct. After surgical tumor resection, 5 year-survival rates in recently reported series vary between 20%-50% and median survival between 15-40 months [1] [2] [3] [4] . The value of either neo-adjuvant or adjuvant treatment has never been studied in well-designed prospective randomized studies. Postoperative irradiation has been administered in several institutions on the basis of a low occurrence of microscopic free margins at the pathological analysis of the surgical specimen. However, in a recent report, the group of the Johns Hopkins Hospital concluded that postoperative radiotherapy did not add any benefit to surgery alone [5] . Unfortunately, at the moment of diagnosis only 20%-40% of patients are candidates for tumor resection and during surgery about 40% of the patients will have a resectable tumor [1; 6; 7] . In the non-resected group, either percutaneous or endoscopic drainage, surgical bypass or placing of a stent during surgery will be performed for treatment of obstructive jaundice and pruritus. The prognosis of this group of patients is very poor, median survival between 4-11 months [8] [9] [10] . Particularly intraluminal radiotherapy is gaining interest as palliative treatment of patients with unresectable tumors [11] [12] [13] [14] . Our experience in the treatment of extrahepatic bile duct cancer has already been reported [15] [16] [17] [18] . In the present paper the treatment results will be analysed, particularly focussing on aspects dealing with either external beam irradiation or intraluminal brachytherapy. The literature on these topics will also be reviewed.
Patients and methods

Patients
Between 1985 and 1995, 109 patients received radiotherapy at the Radiation Oncology Department of the Academic Medical Centre in Amsterdam. All tumors were located in the hepatic ducts, confluence or common bile duct (CBD). Patients with tumors in the gallbladder and periampullary region were not included in the analysis. In 71 patients (group I), tumor resection was combined with either postoperative irradiation (52 patients) or preoperative and postoperative irradiation (19 patients). Thirty-eight patients (group II) were irresectable during surgery [ 16] or primarily inoperable [22] folio wing the diagnostic workup and they were treated with radiotherapy in combination with biliary drainage. Gastroenterologists and surgeons following well-established protocols evaluated all patients. It has been the policy during the time under review to advise postoperative radiotherapy to resected patients. The patients treated with radiotherapy and drainage constitute a selected group giving informed consent after explaining the possible advantages and disadvantages of the treatment. The median age of the whole group was 59 years, range 22 to 77 years. The mean and median age in groups I and II were not significantly different There were 50 females and 59 male patients. All patients had a WHO performance below 2. After treatment, patients were followed at intervals of 3 months the first two years and every 6 months thereafter. Mean follow-up was 25 months ± 23([range 1-108).
Surgery
The surgical procedure has been previously reported [19] . Tumor resection and hepaticojejunostomy were performed in 56 patients in group I and the other 15 patients underwent tumor resection plus hemihepatectomy. In 41 patients the Roux-en Y loop was not closed but brought to the abdominal wall, creating a temporary jejunostomy which was then used for the intraluminal brachytherapy. In patients found unresectable at laparotomy biliary drainage was restored by either a hepaticojejunostomy orplacing an endoprostheses and if considered necessary a gastroenterostomy was also performed. Analysis of the surgical specimen showed involved margins (Rl-resections) in 69 out of 71 cases. Positive margins at the hepatic ducts (upper margin) and/or common bile duct flower margin) were found in 66 patients. The majority of these patients also had pofUive histological margins at the dissection planes. The pathological diagnosis in the nonresected group was established by biopsy during laparotomy in 16 patients and in the other 22 patients by cytological analysis, brush at ERCP or transabdominal fine needle biopsy. Patients without confirmed diagnosis were excluded of the study.
Radiotherapy
External Beam Radiotherapy
Group I (resection + radiotherapy): Inl9outof71 patients who underwent tumor resection 10.5 Gy preoperative radiotherapy was given. This dose was administered in 3 fractions of 3.5 Gy, 3 consecutive days followed by surgery 1 to maximum 3 days after the last fraction. The rationale for using preoperative radiotherapy the last years was avoid scars relapses [17] . Target volume was the hepatic hilus including the stenotic area, which was identified by using the ERCP information as well as the position of the endoprostheses. Typical radiation fields were 10 by 10 cm. Two opposite AP/PA fields were used and the dose was specified at midplane.Postoperative external beam irradiation started once the patient fully recovered from surgery. Median time between surgery and radiotherapy was 57 days ± 35. The center of the target volume was the site of the biliodigestive anastomosis. Around these points, guided by clips left during surgery as well as by the postoperative CT-scan in treatment position, radiation fields, usually 3 or 4, were used encompassing a mean volume of 524 cc ± 250. Radiation was applied using 10 MV photons energy. CT-scan based computer planning dosimetry was performed in all patients avoiding as much as possible high doses in the liver, small bowel and kidneys. It was not the intention to include in the irradiation fields all lymphatic chains in the vicinity of the hepatic hilus, head of the pancreas and small curvature of the stomach. The administered dose was 45 Gy ± 3 Gy in 41 patients who received additional brachytherapy. This dose was given in 3 fractions per day of 1.1 Gy, 4 hours interval between fractions, 5 days per week, 18 days overall time. The other 30 patients were exclusively treated with external beam radiation, mean dose 50 Gy ± 7 Gy also using a similar 3 fractions per day schedule. Patients received H 3 -receptor block medication during radiotherapy and 6 months thereafter.
Group n (unrresectable. radiotherapy + biliary drainage): The target volume in the 38 non-resected patients encompassed the tumor plus a wide margin. As in the resected group lymphatic areas were not intentionally included in the radiation fields. Localisation procedures, computer planning dosimetry, radiation technique and radiation quality were similar as in group I. The mean tumor dose administered with external beam radiotherapy was 48 Gy ± 10. The 19 patients without additional brachytherapy received a mean dose of 56 Gy ± 12 as compared to a mean dose of 40 Gy ± 7 in the other 19 patients getting brachytherapy. Ten patients in this group also received preoperative radiotherapy, 10.5 Gy.
Brachytherapy
Group I (resection + radiotherapy): In the resected group brachytherapy catheters were placed in the hepaticojejunal anastomosis using the Rouxen-Y loop previously prepared during surgery. This procedure was performed under endoscopic control. The objective of brachytherapy was to boost selectively the place of all created anastomosis. The position of the catheters with dummy sources was checked at the simulator where also orthogonal x-rays were done for dosimetry. Indium-192 wires 5 to 7 cm active length were used to load the catheters. Mean specific activity was 2.3 ± 3 milicurie/cm The radiation dose was specified at 1 cm from the sources if only linear geometry of the sources could be achieved. If the anastomosis were more distant one from another and the radioactive sources considerably diverged, a volume around the sources was defined which external edge was 1 cm from the more lateral sources. Forty-one patients were treated in this way. Mean dose was 10.4 Gy ± 1.6 at a mean dose rate equal to 72 cGy/hour ± 40 at 1 cm from the sources. In general 3 iridium wires were used. Group II (unresectable. radiotherapy + biliary drainage): Within group n, non-resected, 19 patients received brachytherapy boost. Under endoscopic control one or two nasobiliary probes were placed at the tumor site. In patients with tumor invading both hepatic ducts not always was possible to cross the stenotic ducts with the catheter so that a part of the tumor probably received a low boost dose. Simulator and planning procedures were similar as in group I. The mean dose at 1 cm from the sources was 21 Gy ± 6 at a mean dose rate of 73 cGy/hour.
Statistics
Univariate analysis of possible prognostic factors related to patient, tumor and treatment characteristics was performed using Kaplan-Meier survival curves and the log-rank significance test for comparison of survival between groups. Patients were censored, as they were alive without clinical evidence of disease at the moment of the analysis. All other patients were considered as events either they died from tumor progression or were alive with known progressive disease at the moment of the analysis. A forward stepwise Cox regression analysis was also performed in the group of 71 patients who underwent tumor resection. Only variables which had pvalues £ 0.10 in the univariate analysis were entered in the Cox regression analysis.
Results
The survival rates at 1, 3, and 5 year in the whole group of 109 patients were 75%, 33%, and 23%, respectively. Median survival was 21 months.
Group I (resection + radiotherapy)
The survival rates at 1, 3 and 5 year were 84%, 37% and 24%, respectively. Median survival was 24 months. Patients 50 year old or younger had a favorable prognosis as also it was the case for well/moderate differentiated tumors. The small group of 9 patients who had negative dissection margins, independently of the status of the upper (hepatic) and lower (choleducus) resection margin, had significandy longer median survival. Patients not completely recovered from the obstructive jaundice as noted by an increasd alkaline phosphatase also had an unfavourable prognosis. Other factors such as gender, lymph node status, year of treatment and type of surgery did not influence prognosis. Analysis of factors related to the radiation treatment showed that a summed preoperative, postoperative and brachytherapy total dose above 55 Gy had a significant negative influence on survival. Neither preoperative irradiation nor brachytherapy had any effect on prognosis. Within the group of patients receiving brachytherapy, subgroup analysis of dose rate at 1 cm from the sources (<; 65 cGy/hour versus >65cGy/hour), brachytherapy doses (s 10 Gy versus > 10 Gy), number of sources (1 versus >1) and length of the sources (s 4 cm versus >4 cm) did not affect the survival. The groups were, however, too small to draw definitive conclusions.
Group II (unresectable, radiotherapy + biliary drainage)
The median disease free survival of 38 non-resected patients was 10.5 months. Survival rates at 1 and 2 years were 43% and 10%, respectively (Fig. 1) . It is noteworthy that patients with an unresectable tumor at laparotomy had a significant better prognosis that patient with a tumor considered primary unresectable. Probably related to this fact is that patients treated with preoperative radiotherapy also had a 17/01/99favourable prognosis, The group of patients receiving brachytherapy as a part of the radiation treatment showed a trend (p=0.06) to live shorter than patiets treated exclusively with external beam irradiation In groups I and n, a total of 60 patients received brachytherapy. Median survival of these patients was 16 months as compared to 22 months in the 49 patients without brachytherapy, but this survival difference was not significant (p=0.29). Among the 60 patients receiving brachytherapy, dose rate at 1 cm (*65cGy/hour versus > 65 cGy/hour), and length of the sources (s 4 cm versus > 4cm) did not have any significant influence on prognosis.
Cox Regression Analysis
A Cox regression forward stepwise analysis was done in the group of patients undergoing tumor resection. Age (s 50 versus > 50 year old), dissection margins (negative versus positive), type of surgery (resection alone versus resection plus liver lobectomy), differentiation grade (good /moderate versus poorly differentiated), alkaline phosphatase preradiotherapy value (<; 120 versus > 120 mmol/1), and total radiation dose (s 55 Gy versus >55 Gy), were entered in the analysis as categorical covariates. Only the pre-radiotherapy alkaline phosphatase value (p=0.02) and the differentiation grade (p=0.03) remained as independent variables.
Complications
In the entire group of 109 patients, acute complications attributable to the external beam irradiation were nausea and vomiting, requiring medication in 16% of the patients. Median weight before radiation was 63 kg ± 26 and the nadir weight during radiotherapy was 62 kg ± 29. No haematological complications were observed. In group I, planned irradiation was completed in all but 3 patients who stopped treatment because leakage of the temporary jejunostomy. In general, the jejunostomy was experienced by the majority of the patients as a considerable burden requiring a surgical intervention for closing. This procedure was abandoned in 1992 and at this time also brachytherapy was not further administered to surgically resected patients. Sixteen patients in group II had episodes of cholangitis during radiation treatment requiring antibiotics and in 6 patients changes of the endoprosthesis.
In group II, the brachytherapy procedure through a nasobiliary probe under endoscopic control was a considerable burden. In spite of sedation, pain and nausea occur in practically all patients. Prophylactic administration of antibiotics is required during the brachytherapy treatment. In the group of resected tumors the two more frequent observed late complications were stenosis of the biliodigestive anastomosis in 6 patients and gastroduodenal 217 bleeding in 6 patients. During follow up, episodes of cholangitis, frequently transient, were observed in 21 out of 71 (30%) patients. In non-resected patients, obstructive syndrome is the overwhelming problem. In 29 out of 38 patients (76%), replacement of the endoprostheses was required to solve this problem.
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Figurel: Actuarial overall survival curves in resected (Group I) and nonresected (Group II) patients proximal bile duct tumors. RT=radiotherapy.
Causes of death
At the moment of the analysis 19 % of the patients, 16 in group I and 5 patients in group II, were alive without evidence of progressive disease. Local tumor recurrence was observed in 64 patients (59%), 35 in group I and 29 in group II. Isolate distant metastases, liver and peritoneal, were present in 14 patients (13%). Four patients died probably due to complications (severe bleeding) and 3 other patients died because intercurrent disease (a second tumor in two cases). Sixteen patients survived 4 year or longer after treatment, all in the group undergoing tumor resection. The longest observed survival in the non-resected patients was 40 months.
Discussion
The results obtained in our study correspond quite well with other reported series, which have included patients with similar characteristics [14, 20, 36] . In a study by Kamada et al. [20] including 145 patients, median survival times of respectively, 21.5 months and 12.4 months were achieved in resected and unresectable patients receiving postoperative irradiation and radiation alone. Veeze-Kuipers et al. [14] reported a median survival of 15 months when postoperative irradiation was given to patients with Rl resections and 8 months if tumors were unresectable and treated with external plus intraluminal radiotherapy. Several authors agree that particularly in microscopic irradical resections, Rl, postoperative radiotherapy improves long-term survival [21] [22] [23] .
Cameron et al. [1] noted that radiotherapy extends survival in patients undergoing a palliative stenting but not in those undergoing resection. Pitt et al. [5] , from the same institution, recently reported a similar survival in comparable patients treated with or without radiotherapy, but this study was non-randomised. Patients receiving brachytherapy in the series by Kamada et al. [20] showed significantly better survival than patients treated with external beam radiation alone. This was not the case in our experience. Other factors such as type of surgery, age, sex, primary tumor location and lymph node involvement had no effect on survival. Klempnauer et al. [4] , in a series including 151 patients treated with surgery alone, identified tumor size, lymph node status, residual tumor (RO, Rl, R2) and differentiation grade as factors with prognostic impact, in the univariate analysis.
In the multivariate analysis, only lymph node status and residual tumor remained independent prognostic indicators. All our patients but two had Rl resections so that it is not possible to include this factor in the analysis. In our series, lymph node status had no effect on survival but the differentiation grading was one independent prognostic indicator in the multivariate analysis. Elevated alkaline phosphatase levels could reflect an irreversible hepatic damage or a suboptimal drainage, circumstances which may influence the long-term survival. In reported series where postoperative irradiation was given, the target volume is not always described. For external beam radiotherapy the target volume included the known tumor and/or the site with a high risk of relapse [20] , the biliodigestive anastomosis [12] , or the porta hepatis, common bile duct and regional lymph nodes (hepatoduodenal ligament and upper pancreaticoduodenal nodes) [14] . Our radiation portals only included the site of the anastomosis with a margin of 1.5-2 cm in all directions. We would advise to use limited fields in order to avoid toxicity. If brachytherapy is to be used as a boost, the sources are placed at the the hepaticojejunal anastomosis using the technique of percutaneous transhepatic cholangiography with drainage (PTCD) [24] . Our technique by creating a temporary jejunostomy was technically difficult to perform, the localization of the anastomosis was sometimes not possible and further frequent leakage problems were a burden for the patients. For these reasons and also because no survival improvement was observed in the patients treated with brachytherapy, actually we treat the patients with external radiotherapy alone.The administered radiation doses vary in the reported series and also depend on the use or not of brachytherapy. In general, a total dose of about 55 Gy is advised, 40 Gy -45 Gy external beam and 10 Gy -20 Gy brachytherapy specified at 1 cm from the sources [1; 5; 12; 14; 22] . In the adjuvant setting, we agree not to give total doses higher than 55 Gy. Our results showed that doses above this level could negatively influence survival.
Because during the first year following resection implantation metastases in the surgical scars were observed in 15% [8/52] of patients [25] , we decided in 1990 to administer a short course of preoperative irradiation, 3 times 3.5 Gy in 3 consecutive days, aiming at an impairment in the viability of tumor cells which are spilled during surgery. Since the introduction of this policy no recurrences in the surgical scar have been observed. Kamada et al. [20] reported on 9 patients treated with preoperative brachytherapy at doses between 40-90 Gy (specified at 0,5 cm from the sources) and they conclude that brachytherapy preoperatively was probably counterproductive, causing serious biliary bleeding. No other experiences with preoperative radiotherapy have been reported. Duodenal bleeding, duodenal obstruction and stenosis of the biliodigestive anastomosis causing disturbances in the biliary drainage are the more frequent complications following resection with or without radiotherapy. The rate of late complications, 9% duodenal obstruction, 8% upper digestive tract bleeding and 30% episodes of cholangitis correspond with other reported series [5; 12; 14; 22] . The possible contribution of radiotherapy to the origin of these complications cannot be established. Pitt et al. [5] found no differences in duodenal obstruction, small intestine problems, liver toxicity and occurrence of liver abscesses between radiated and non-radiated patients.
The prognosis of patients with unresectable tumors differs according to the approach used for the biliary drainage. Median survival is 2-7 months after percutaneous transhepatic endoprostheses, 9-14 months after palliative biliary enteric bypass and 8-14 months following operative transtumoral stenting (see for a review reference [2] ). In Table 1 a summary of results obtained in non-resected patients treated with biliary drainage plus intraluminal brachytherapy, either or not combined with external beam irradiation is presented. The differences in median survival between series are probably the result of patient selection as well as how the biliary drainage was achieved. The median survival of 17 months obtained in one of the first reported series [13] using a relatively low dose of intraluminal brachytherapy alone has not been emulated in more recent series. In general, it seems that if the biliary drainage is restored following a surgical procedure median survival is 12-13 months [26; 27] in comparison to a median survival of 8-10 months when PTCD orERCP is performed [1; 12; 28-30] . However, this difference in survival could be caused by a better general condition and less tumor load in patients undergoing surgery. In our series patients found unresectable at laparotomy had a significant better median survival than patients primarily unresectable, 18 months versus 8 months, respectively. Administered radiation doses were very similar in the majority of the series. Median doses of external beam radiation were between 40 -50 Gy and median doses of 20 -25 Gy specified at 1 cm from the sources were given as a boost using intraluminal brachytherapy. Although limited by the small number of patients univariate analysis of prognostic factors disclosed the comparison between tumors primarily unresectable versus tumors unresectable at laparotomy as significant. Age, sex, tumor location and total dose did not influence the prognosis. Patients receiving preoperative irradiation have a tendency to have a longer median survival which probably correlated to unresectability during laparotomy. Surprisingly patients treated with brachytherapy had a shorter survival than patients treated with external beam irradiation alone (p=0.06). We could not find an explanation for this fact. When patients were stratified by the factor primary unresectability versus unresectability at laparotomy, a significant longer survival (p=0.02) was observed if brachytherapy was not given in the group "laparotomy" but not in the primary unresectable group. As it was the case for resected tumors, the reported series do not always provide information about the target included in the radiation fields. Our portals encompassed the tumor at the hilus or CBD with a margin without intending to treat all the regional lymph node areas. The last years 3-D planning dosimetry has been introduced using spiral CTscan for tumor delineation and localization of the organs in the upper abdomen.
It is not yet proved that radiotherapy and in particular the increasing use of brachytherapy, influence the natural course of the disease after reestablishment of the biliary drainage. Pitt et al. [5] prospectively stratified 19 patients treated palliatively by radiotherapy or no radiotherapy. They did not observe differences in survival. Bowling et al. [28] in an interesting paper retrospectively compared endoscopic stenting alone (28 patients) with stenting plus radiotherapy (28 patients) in non-resected patients. The patients in the group without radiotherapy were recommended to receive radiation but never pursued. The two groups were well matched for sex, age, and type of stricture. Median survival was not significantly different between the two groups but during the first 9 months there was a survival advantage in the radiotherapy group. This difference became significant (p=0.01) if only patients with stricture type II and type III were considered. However, since this improvement in survival was at the price of longer hospital stay and more stent changes per patient, the authors raise doubts over the routine use of radiotherapy in the management of nonresectable cholangiocarcinoma. Gastric and duodenal obstruction as well as duodenal ulceration and bleeding are the most frequently found complications following radiotherapy in non-resectable cholangiocarcinoma [12; 14; 31] . We did not observe these problems but frequent episodes of cholangitis were the dominant complications requiring stent changes. Whether radiotherapy did play a role in the occurrence of cholangitis is impossible to assert.
Intraoperative radiotherapy seems to increase the survival of patients with unresectable tumors [32; 33] , however this treatment modality is only available in few centres. Chemotherapy (see for review [34] ) in various combinations achieves responses in about 30% of the patients and in a randomised trial beneficially influenced survival and quality of life. Results after combined chemotherapy and radiotherapy are encouraging, median survivals between 12-30 months have been reported [35, 37] .
In conclusion, our results compare quite well with other published series. We could not demonstrate that patients receiving a boost dose using intraluminal brachytherapy had a better survival than patients treated with external beam irradiation alone. That was the case in both patient groups with resectable and unresectable tumors. Although no survival improvement was observed, low dose preoperative irradiation seems to diminish the recurrences in the surgical scars. Prospective randomised studies are still lacking but these are the only way to demonstrate the value of new treatment strategies. Quality of life and cost-benefit aspects should also be incorporated as an objective of these studies.
